Netherlands Cancer Institute switches to new digital pathology platform

The platform, Concentriq Dx is designed to expand digital pathology practice, laying the foundation for its pathologists to deliver personalized diagnoses that better inform treatment decisions. In doing so, the cancer center, which houses an internationally acclaimed research institute, will generate additional pathology data that can lead to clinical breakthroughs, Proscia predicts. 

Digital pathology, which shifts the 150-year-old standard of care from microscope to whole slide image, is increasingly powering routine diagnosis as expectations for precision medicine intensify the impact of the pathologist shortage and rising cancer burden. An early adopter, NKI recognized that scaling its digital operations to further deliver on its commitment to excellent patient care would require moving away from its legacy software system. It selected the enterprise-grade Concentriq Dx to serve as the modern platform at the center of its growing oncology practice.

CE-marked under IVDR, Concentriq Dx is a singular, secure digital pathology platform that drives primary diagnostic and other routine workflows across the connected laboratory.* NKI will draw on the platform’s interoperability to unify images from disparate scanners, bringing more pathology data into its practice. With live and asynchronous collaboration and remote image viewing, the solution helps pathologists to broaden access to specialists in an effort to provide higher quality diagnoses. The platform also offers interoperability with third-party image analysis applications, allowing NKI to identify clinically impactful patterns, and is designed for realizing the promise of pathology’s computational future.

“Concentriq Dx will empower us to chart our path towards full digitization,” said José van den Berg, Head of the Department of Pathology at NKI. “The modern, enterprise-grade platform will enable us to increasingly combine expertise and insight to drive precision diagnosis. Our multidisciplinary teams work to provide personalized treatment for all patients, and our pathology data plays an integral role in achieving this aim.” 

In addition to informing diagnoses, pathology data factors heavily into biomedical research that leads to new therapies and other breakthroughs that advance precision medicine and improve patient care. NKI’s internationally acclaimed research institute works closely with its dedicated cancer center to create maximum impact for patients through foundational and translational clinical studies. By scaling its digital pathology practice, NKI is paving the way to unlock even more value from its growing volume of data by increasingly incorporating it into research initiatives. “We are thrilled to help NKI take the next step on its digital pathology journey with Concentriq Dx,” said Arun Ananth, Proscia’s Chief Commercial Officer. “As we continue to expand our presence in Europe, we look forward to working with a world-class team that is committed to its patients through excellent clinical care and groundbreaking research.”

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the Covid-19 public health emergency. 

Source: Proscia 

19.01.2023

• cancer (914)
• digital pathology (62)
• digitisation (66)
• pathology (251)
• personalised medicine (240)